Login or sign up
For business

Access Pharmaceuticals

4.0· 10 reviews
Average ratingGreat
4.0/ 5

Based on 10 reviews

530%
440%
330%
20%
10%
Ask AI

Ask Trustburn about Access Pharmaceuticals

Based on 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Cindy Angus
Reviews 1

Access Pharmaceuticals has been my go-to for medical supplies. Their website is user-friendly and the quality of their products is unmatched. The customer service team is always helpful and knowledgeable. I would highly recommend them to anyone in need of medical supplies.

Gustavo Gonzalez
Reviews 1

Access Pharmaceuticals is an excellent company. Their website is user-friendly and easy to navigate. I have been using their products for the past year and have never been disappointed. The quality is top-notch and the customer service is outstanding. I highly recommend Access Pharmaceuticals to anyone in need of their products.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Access Pharmaceuticals

Access Pharmaceuticals (ACCP.ob) is an emerging pharmaceuticals company with a focus on oncology and diabetes.

Access has one FDA approved treatment for oral mucositis (MuGard) which has been launched commercially in Europe and will be launched elsewhere in 2009.

ProLindac, a novel DACH platinum chemotherapy, recently completed a Phase 2a trial in recurrent ovarian cancer and will enter combination trials shortly; ProLindac is partnered in the Far East and ACCP is actively seeking North American and European co-development partners.

Additionally, ACCP has a novel nucleoside analogue, Thiarabine, which will enter Phase 2 leukemia trials this year, a preclinical stage monoclonal antibody (Angiolix) and additional preclinical oncology programs.

Also, ACCP has an oral insulin and oral human growth hormone program which is being developed in a sponsored research agreement with a major pharmaceutical company (and for which ACCP is seeking additional development partnerships).